Synthesis of 11C-Radiolabeled Eribulin as a Companion Diagnostics PET Tracer for Brain Glioblastoma

The successful 11C-radiolabeling of eribulin, an analog of the marine natural product halichondrin B, and an approved anticancer drug for the treatment of breast cancer and liposarcoma, is reported. A rapid sequence involving a nitroaldol reaction with [11C]nitromethane and subsequent reduction of t...

Full description

Saved in:
Bibliographic Details
Published in:Bulletin of the Chemical Society of Japan 2023-03, Vol.96 (3), p.283-290
Main Authors: Niwa, Takashi, Tahara, Tsuyoshi, Chase, Charles E, Fang, Francis G, Nakaoka, Takayoshi, Irie, Satsuki, Hayashinaka, Emi, Wada, Yasuhiro, Mukai, Hidefumi, Masutomi, Kenkichi, Watanabe, Yasuyoshi, Cui, Yilong, Hosoya, Takamitsu
Format: Article
Language:English
Subjects:
Accumulation
Aldehydes
Brain
Brain cancer
Breast cancer
Medical imaging
Natural products
Nitromethane
Optimization
Positron emission
Radiochemistry
Radiolabelling
Reduction
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The successful 11C-radiolabeling of eribulin, an analog of the marine natural product halichondrin B, and an approved anticancer drug for the treatment of breast cancer and liposarcoma, is reported. A rapid sequence involving a nitroaldol reaction with [11C]nitromethane and subsequent reduction of the nitro group enabled the introduction of a carbon-11 atom at the C35-position of eribulin. Optimization of the reaction and purification conditions led to a reproducible synthetic method for [35-11C]eribulin with 248 ± 104 MBq of radioactivity, 88.2 ± 5.8% radiochemical purity, and 132 ± 32 MBq/nmol molar activity. The total synthetic time was 38.0 ± 1.3 min (n = 12). PET imaging using mice bearing brain tumors revealed a specific accumulation of [35-11C]eribulin in tumors without any significant metabolic changes. These results indicate the applicability of [35-11C]eribulin for the quantitative measurement of eribulin migration into tumor tissue, which would be beneficial for exploring the application of eribulin for glioblastoma treatment and estimating the appropriate dosage for each patient.
ISSN:0009-2673
1348-0634
DOI:10.1246/bcsj.20220335